MedTrace Logo

Soluble Forms and Ligands of RAGE in ALI/ARDS (SoLiRAGE).

NCT01270295 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2013-03-13

No results posted yet for this study

Summary

RAGE, the receptor for advanced glycation end products, is a novel marker of alveolar epithelial type I cell injury. Soluble RAGE (sRAGE) is elevated in the plasma and in the pulmonary edema fluid from patients with ALI/ARDS, but one should acknowledge that the RAGE/NF-B axis is also involved in the pathophysiology of various other conditions. Few data are available about the levels of soluble forms and ligands of RAGE in the setting of ALI/ARDS. The purpose of this observational prospective study is to describe soluble forms (sRAGE, esRAGE) and ligands of RAGE (HMGB-1, S100A12, AGEs) levels in ICU patients with ALI/ARDS.

Conditions

  • Acute Lung Injury
  • Acute Respiratory Distress Syndrome
  • Mechanical Ventilation

Sponsors & Collaborators

  • University Hospital, Clermont-Ferrand

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01270295 on ClinicalTrials.gov